Submitted by Anonymous (not verified) on 7 September 2023 - 13:28
Human medicines European public assessment report (EPAR): Emgality, galcanezumab, Migraine Disorders, Date of authorisation: 14/11/2018, Revision: 10, Status: Authorised
Source: